Medicare’s new technology bonus payments
Executive Summary
CMS is proposing a July 1 FDA approval deadline for products that are candidates for extra reimbursement under Medicare's inpatient payment rules. Medicare boosts hospital reimbursement for technologies that have been on the market for less than three years, demonstrate "substantial clinical improvement" over existing therapies, and would not be adequately reimbursed by Medicare. CMS says a July deadline would allow time for adequate review and avoid devoting resources to in-depth evaluation of products that do not come to market in time for a final decision by Oct. 1, when the add-on payments take effect. The change is outlined in proposed rules governing the Medicare inpatient prospective payment system for FY 2009, slated for Federal Register publication April 30
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.